The global urinalysis market was valued at USD 2.14 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2030. This growth is driven by increasing incidences of diseases such as urinary tract infections (UTIs), diabetes, and kidney diseases. For example, the National Diabetes Statistics Report of 2020 revealed that approximately 34.1 million U.S. adults aged 18 and older had diabetes, with about one-third also experiencing kidney-related complications due to high blood sugar and blood pressure. Urinalysis serves as an effective, noninvasive diagnostic method for identifying kidney diseases, and the rising prevalence of such conditions is expected to boost demand for urinalysis products, thereby driving market expansion.

The COVID-19 pandemic initially impacted the market due to reduced hospital visits and lower sales of urine analysis tests during nationwide lockdowns, which restricted access to diagnostic and hospital services. However, testing numbers have rebounded as restrictions eased.

Urinalysis is also gaining importance in diagnosing post-COVID-19 complications, such as acute kidney and tubular injuries. A 2021 study by Columbia University highlighted two biomarkers, kidney injury marker-1 (KIM-1) and urinary NGAL, as effective for detecting kidney and tubular injuries, underscoring the growing relevance of urinalysis in post-pandemic healthcare.

Gather more insights about the market drivers, restrains and growth of the Global Urinalysis Market

Emerging markets like South Korea, Brazil, India, and Mexico present significant opportunities for market players due to factors such as a growing burden of chronic diseases, enhanced healthcare infrastructure, a large patient base, and rising disposable incomes. For instance, India’s healthcare expenditure increased from USD 232.73 million in 2020 to USD 507.97 million in 2021.

Governments are also initiating screening programs for early detection of urinary and renal disorders. For example, over a decade ending in March 2021, a school-based urinary analysis program in Wenzhou, China, screened 12,497 primary and secondary school students, identifying abnormalities in 36% of primary and 95% of secondary students. Such initiatives are expected to fuel demand for urinalysis tests.

Investments in home-based urine testing kits are further supporting market growth. For instance, Vivoo raised USD 6 million in November 2021 to develop at-home urine tests for lifestyle and nutrition guidance. The focus on affordable urinalysis solutions is particularly relevant for price-sensitive markets. Additionally, initiatives like the Maple Syrup Urine Disease Fund’s "Million Dollar Bike Ride" raised over USD 1 million in 2022 to support research into disease treatments.

Regional Insights:

North America Urinalysis Market Trends

North America led the market in 2022, accounting for 38.3% of global revenue. This dominance is attributed to strategic initiatives by key players, such as licensing agreements. For example, in August 2020, Sysmex and Siemens Healthcare GmbH entered an agreement to distribute Siemens’ CLINITEK Novus urine analyzers in North America, contributing to regional growth.

Approximately 40% of women in the U.S. are estimated to develop a UTI during their lifetime, as per the National Center for Biotechnology Information (NCBI). Moreover, chronic kidney disease (CKD) affects 37 million people in the U.S., highlighting the need for effective diagnostics and driving regional market growth.

Asia Pacific Urinalysis Market Trends

The Asia Pacific region is anticipated to be the fastest-growing market, with a CAGR of 5.7% from 2023 to 2030. Factors such as local urine analyzer manufacturers, increased adoption of advanced diagnostic tools, and a large patient base with unmet needs are propelling growth in the region.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

Key Companies and Market Developments

Leading companies are focusing on strategies like mergers, acquisitions, and technological advancements. In December 2021, KDx Diagnostics, Inc., and Lister Hospital launched KDx's URO17 noninvasive bladder cancer urine test in the UK, enhancing market presence. Siemens Healthineers launched a urine chemistry analyzer in 2022 and acquired Acon Laboratories in January 2023, further expanding its product portfolio.

Other notable acquisitions include Abbott's acquisition of Alere, a leader in point-of-care diagnostics, and Danaher’s acquisition of Beckman Coulter, a prominent provider of laboratory instruments and consumables. These developments underscore the dynamic competitive landscape of the urinalysis market.

Key Urinalysis Companies:

Order a free sample PDF of the Urinalysis Market Intelligence Study, published by Grand View Research.